We are using cookies to implement functions like login, shopping cart or language selection for this website. Furthermore we use Google Analytics to create anonymized statistical reports of the usage which creates Cookies too. You will find more information in our privacy policy.
OK, I agree I do not want Google Analytics-Cookies
The International Journal of Oral & Maxillofacial Implants
Login:
username:

password:

Plattform:

Forgotten password?

Registration

Int J Oral Maxillofac Implants 24 (2009), Supplement     30. Oct. 2009
Int J Oral Maxillofac Implants 24 (2009), Supplement  (30.10.2009)

Supplement, Page 12-27, PubMed:19885432


Systemic Conditions and Treatments as Risks for Implant Therapy
Bornstein, Michael M. / Cionca, Norbert / Mombelli, Andrea
Purpose: To evaluate whether systemic diseases with/without systemic medication increase the risk of implant failure and therefore diminish success and survival rates of dental implants.
Materials and Methods: A MEDLINE search was undertaken to find human studies reporting implant survival in subjects treated with osseointegrated dental implants who were diagnosed with at least one of 12 systemic diseases.
Results: For most conditions, no studies comparing patients with and without the condition in a controlled setting were found. For most systemic diseases there are only case reports or case series demonstrating that implant placement, integration, and function are possible in affected patients. For diabetes, heterogeneity of the material and the method of reporting data precluded a formal meta-analysis. No unequivocal tendency for subjects with diabetes to have higher failure rates emerged. The data from papers reporting on osteoporotic patients were also heterogeneous. The evidence for an association between osteoporosis and implant failure was low. Nevertheless, some reports now tend to focus on the medication used in osteoporotic patients, with oral bisphosphonates considered a potential risk factor for osteonecrosis of the jaws, rather than osteoporosis as a risk factor for implant success and survival on its own.
Conclusions: The level of evidence indicative of absolute and relative contraindications for implant therapy due to systemic diseases is low. Studies comparing patients with and without the condition in a controlled setting are sparse. Especially for patients with manifest osteoporosis under an oral regime of bisphosphonates, prospective controlled studies are urgently needed.

Keywords: bisphosphonates, diabetes, implant failure, osseointegration, osteoporosis, systemic disease